FDA expands use of AstraZeneca/Merck ovarian cancer drug

(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck& Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news